ianalumab (VAY736) - Novartis
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - Oct 13, 2026 - P2 | N=201 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting 
Enrollment closed • Immunology • Scleroderma • Systemic Sclerosis • CRP
http://clinicaltrials.gov/ct2/show/NCT06470048
 
Oct 13, 2026
 
Prev Next